- Open Access
Cooperative contributions of Interferon regulatory factor 1 (IRF1) and IRF8 to interferon-γ-mediated cytotoxic effects on oligodendroglial progenitor cells
© Horiuchi et al; licensee BioMed Central Ltd. 2011
Received: 9 October 2010
Accepted: 24 January 2011
Published: 24 January 2011
Administration of exogenous interferon-γ (IFNγ) aggravates the symptoms of multiple sclerosis (MS), whereas interferon-β (IFNβ) is used for treatment of MS patients. We previously demonstrated that IFNγ induces apoptosis of oligodendroglial progenitor cells (OPCs), suggesting that IFNγ is more toxic to OPCs than IFNβ. Thus we hypothesized that a difference in expression profiles between IFNγ-inducible and IFNβ-inducible genes in OPCs would predict the genes responsible for IFNγ-mediated cytotoxic effects on OPCs. We have tested this hypothesis particularly focusing on the interferon regulatory factors (IRFs) well-known transcription factors up-regulated by IFNs.
Highly pure primary rat OPC cultures were treated with IFNγ and IFNβ. Cell death and proliferation were assessed by MTT reduction, caspse-3-like proteinase activity, Annexin-V binding, mitochondrial membrane potential, and BrdU-incorporation. Induction of all nine IRFs was comprehensively compared by quantitative PCR between IFNγ-treated and IFNβ-treated OPCs. IRFs more strongly induced by IFNγ than by IFNβ were selected, and tested for their ability to induce OPC apoptosis by overexpression and by inhibition by dominant-negative proteins or small interference RNA either in the presence or absence of IFNγ.
Unlike IFNγ, IFNβ did not induce apoptosis of OPCs. Among nine IRFs, IRF1 and IRF8 were preferentially up-regulated by IFNγ. In contrast, IRF7 was more robustly induced by IFNβ than by IFNγ. Overexpressed IRF1 elicited apoptosis of OPCs, and a dominant negative IRF1 protein partially protected OPCs from IFNγ-induced apoptosis, indicating a substantial contribution of IRF1 to IFNγ-induced OPC apoptosis. On the other hand, overexpression of IRF8 itself had only marginal proapoptotic effects. However, overexpressed IRF8 enhanced the IFNγ-induced cytotoxicity and the proapoptotic effect of overexpressed IRF1, and down-regulation of IRF8 by siRNA partially but significantly reduced preapoptotic cells after treatment with IFNγ, suggesting that IRF8 cooperatively enhances IFNγ-induced OPC apoptosis.
This study has identified that IRF1 and IRF8 mediate IFNγ-signaling leading to OPC apoptosis. Therapies targeting at these transcription factors and their target genes could reduce IFNγ-induced OPC loss and thereby enhance remyelination in MS patients.
Persistent demyelination often follows recurrent inflammation in multiple sclerosis (MS), even though oligodendroglial progenitor cells (OPCs) are present in the adult CNS as a potential source of oligodendrocytes for remyelination after loss of myelin [1–3]. As a pathological mechanism underlying this remyelination failure, accumulating evidence indicates that interferon-γ (IFNγ), the only type II IFN secreted into the lesions by infiltrating T helper 1 (TH1) cells and natural killer cells, induces cytotoxic effects on OPCs, and inhibits their differentiation, leading to failure in de novo myelination by OPCs [4–9]. We also demonstrated in our previous study that actively proliferating OPCs are far more susceptible to cytotoxic effects of IFNγ than are post-mitotic mature myelinating oligodendrocytes . In contrast to IFNγ, interferon-β (IFNβ), a type I IFN, is used successfully to reduce relapse rates in relapsing remitting MS . However, though IFNβ has minimal adverse effects on proliferation, migration and differentiation of oligodendrocytes in vitro [12, 13], it does inhibit remyelination after cuprizone-induced demyelination in vivo . Given the extensive overlap in type I and type II IFN signaling pathways, our goal in the present study was to determine what molecular mechanisms are responsible for the much greater OPC toxicity of IFNγ than IFNβ.
The janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been well-studied as a principal intracellular signaling pathway activated by IFNs (Reviewed in ). Binding of IFNγ to the type II IFN receptor results in the rapid autophosphorylation and activation of the receptor-associated JAK1 and JAK2, which in turn activates cytoplasmic STAT1 by phosphorylation at Tyr 701. Activated STAT1 proteins form homodimers, which translocate into the nucleus, and initiate transcription by binding to a specific motif, known as the IFNγ-activated site (GAS), in the promoters of various IFN-stimulated genes (ISGs). IFNβ utilizes another receptor, the type I IFN receptor, associated with JAK1 and tyrosine kinase 2 (TYK2), and regulates formation of the heterotrimeric transcription complex, interferon-stimulated gene factor 3 (ISGF3), composed of the activated forms of STAT1 and STAT2, and IRF9/ISGF3γ. ISGF3 recognizes the IFN-stimulated response element (ISRE) which is distinct from the GAS, and activates transcription of another set of ISGs. Although there is a substantial overlap between IFNβ-inducible and IFNγ-inducible ISGs stemming from their common dependence on activation of STAT1 , we hypothesized that IFNγ-mediated cytotoxic effects on OPCs are attributable to ISGs which are differently induced in OPCs by IFNγ than by IFNβ.
As an example of the ISGs which are differently induced between IFNγ and IFNβ, we previously examined IFN-mediated transcriptional induction of major histocompatibility complex class II (MHC-II) molecules in the oligodendroglial lineage . Surface expression of MHC-II becomes detectable in OPCs after treatment with IFNγ, whereas IFNβ fails to induce expression of MHC-II. Our results indicated that the distinct difference in transcriptional activation of interferon regulatory factor 1 (IRF1) between IFNγ and IFNβ is attributed to the difference in subsequent MHC-II expression. Thus, IRF1 is also a promising example of the ISGs responsible for IFNγ-mediated cytotoxic effects in OPCs. In agreement with this idea, involvement of IRF1 in IFNγ-induced OPC apoptosis has recently been reported .
IRF1 was originally isolated as a transcriptional activator of the IFNβ gene in response to viral infection [19, 20]. IRF1 and eight other subsequently identified factors share a highly-conserved amino-terminal DNA binding domain (DBD) with five conserved tryptophan repeats, and thereby constitute a family of transcription factors, termed the IRF family (Reviewed in [21–24]). The DBD forms a helix-turn-helix domain and recognizes similar, if not identical, DNA motifs containing the consensus IRF recognition sequence, 5'-AANNGAAA-3' . IRF2, which shares the highly homologous DBD with IRF1, is considered a transcriptional repressor for IRF1-mediated transcription by competing for the same cis elements [19, 26, 27]. In addition, most of the members, except IRF1 and IRF2, have an IRF association domain (IAD) at the C-terminal region, through which they interact with other members or other transcription factors. Despite the possible functional overlap and interplay among members of the IRF protein family, however, there have been only a few studies on the IRF family members in the oligodendroglial lineage , particularly with respect to their roles in IFNγ-mediated and IFNβ-mediated signaling . In this study, using primary cultures of highly pure OPCs from rats, we performed a comprehensive analysis of all members of the IRF family in OPCs in response to IFNγ and IFNβ, and examined the synergistic roles for IRF1 and IRF8 (also known as interferon consensus sequence binding protein (ICSBP)), in IFNγ-induced OPC apoptosis.
Reagents and chemicals
All reagents and culture media used in this study were purchased from SIGMA (St. Louis, MO, USA) and Invitrogen (Carlsbad, CA, USA), respectively, except for the following products: Human recombinant fibroblast growth factor 2 and platelet-derived growth factor A homodimer were from R&D systems (Minneapolis, MN, USA); rabbit anti-IRF1 and anti-IRF2 antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and mouse anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were from Chemicon (Temecula, CA, USA). Rabbit anti-IRF8 antibody was produced by Ozato's laboratory. Small interfering RNA (siRNA) for IRF2 (siRNA ID: s220597), IRF8 (siRNA ID: s146232), and Negative control siRNA were from Ambion (Austin, TX, USA).
Mixed glial culture
Primary mixed glial cultures from rats were prepared as reported previously . Briefly, whole brains were dissected from 0 to 2-day-old Lewis rats, and submerged in ice-cold Leibovitz's L-15 medium. Under a dissecting microscope, olfactory bulbs, cerebral cortices and hindbrains were removed. After cleaning off meninges and vessels including choroidal plexus, the remaining brain tissues were cut into small chunks with a 21-gauge needle, and digested by 0.0625% (w/v) trypsin in Ca2+ and Mg2+-free Hank's Balanced Salt Solution (HBSS) for 20 min. Dissociated cells were obtained by passing the softened chunks through a 1 ml pipette tip several times, and collected by centrifugation at 365 xg for 5 min. The cells were resuspended in minimum essential medium alpha containing 5% (v/v) fetal bovine serum and 5% (v/v) calf serum, and plated onto a 10 cm culture dish. One day after plating, attached cells (designated as passage 0) were washed with HBSS to remove serum, and thereafter maintained in the medium (GM), a 3:7 mixture (v:v) of B104 neuroblastoma-conditioned medium and the N1 medium (high glucose Dulbecco's modified Eagle's medium supplemented with 6 mM L-glutamine, 10 ng/ml biotin, 5 μg/ml insulin, 50 μg/ml apo-transferrin, 30 nM sodium selenite, 20 nM progesterone and 100 μM putrescine as final concentrations). Cultures were fed with fresh GM medium every other day for approximately 5 days, at which time the proliferating glial cells were almost confluent.
Immunopanning for purification of A2B5+rat OPCs
The mixed glial cultures were washed with Ca2+ and Mg2+-free HBSS, suspended in the N1 medium containing 0.1% (w/v) BSA, and plated and incubated on negative immunopanning plates coated with RAN-2 antibody for 30 min at 37°C to exclude RAN-2-positive cells . Following two rounds of this negative selection, nonadherent cells were transferred to the A2B5 positive panning plates. After the serial immunopanning, purified cultures contained more than 95% of OPCs which were A2B5-positive, O4-negative, and glial fibrillary acidic protein-negative.
Cells cultured on poly-D-lysine-coated coverslips were incubated with A2B5 hybridoma supernatants (undiluted) at room temperature for 30 min. After washing with phosphate-buffered saline (PBS), cells were fixed with 4% paraformaldehyde at room temperature for 15 min, and then permeabilized with 100% methanol at -20°C for 15 min. For IRF8 staining, cells were incubated with anti-IRF8 antibody diluted at 1:50 in PBS containing 5% normal goat serum and 0.03% Triton-X 100 at room temperature for 2 h, after permeabilization by 100% methanol. After incubation with fluorophore-conjugated secondary antibodies (1:50, v:v) in PBS at room temperature for 30 min, nuclei were counterstained with 4,6-diamidio-2-phenylindole (0.5 μg/ml) for 10 min, and then the coverslips were mounted on slide glasses with VectorShield (Vector laboratory, Burlingame, CA, USA).
Protein lysates were prepared in the lysis buffer as described previously . Twenty μg of protein from each sample were size-fractioned by SDS-polyacrylamide gel electrophoresis, transferred onto a nitrocellulose membrane (Schleicher & Schnell, Keene, NH, USA) and probed with primary antibodies for IRF1 (1:400, v:v) and IRF8 (1:5000, v:v) for 1 h. Full range recombinant Rainbow Molecular Weight Markers (Amersham Biosciences, Piscataway, NJ, USA) were used as a reference for molecular sizes. Immunoreactive signals were detected by enhanced chemiluminescence according to the manufacture's protocol (Amersham Biosciences). Equal protein loading was confirmed by subsequent probing with the mouse monoclonal antibody against GAPDH in each experiment.
Caspase activity assay
Cells were homogenized in lysis buffer (100 mM HEPES; 10% (w/v) sucrose; 0.1% (w/v) 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate; 10 mM dithiothreitol; 1 mM EDTA; 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml aprotinin; 1 μg/ml pepstatin; 5 μg/ml leupeptin) . The protein lysates were stored at -80°C until use as a 1:1 (v:v) mixture with glycerol. Caspase activity was measured by a fluorometric method; protein samples (10 μg) were incubated with the fluorogenic substrate, acetyl-Asp-Glu-Val-Asp-α-(4-methylcoumaryl-7-amide) (12.5 μM) (Ac-DEVD-AMC, Peptides international, Luoisville, KY, USA) in 250 μl of the lysis buffer, and cleavage of Ac-DEVD-AMC was monitored by a multiplate spectrofluoromater, Gemini EM (Molecular devices, Sunnyvale, CA, USA) for 60 min at 25°C. The DEVD-cleavage activity was expressed as delta RFU (relative fluorescence unit)/μg protein/h.
5-bromo-2'-deoxyuridine (BrdU)-incorporation assay
OPCs cultured in 60 mm dishes were exposed to a 4 h BrdU pulse (10 μM) just prior to harvesting. The trypsinized cells were collected in GM and resuspended in 1.5 ml PBS. After fixation by 70% (v/v) ethanol at -20°C for overnight, 5 × 104 cells were washed with 1 ml of the washing buffer (0.1% (w/v) BSA in PBS), and denatured by resuspension in 2N HCl at room temperature for 20 min. After resuspending once more in washing buffer, the cells were incubated in 0.1 M sodium borate at room temperature for 2 min to neutralize any residual acid. Cells that had incorporated BrdU following incubation were identified by incubation with a fluorescein isothiocyanate (FITC)-conjugated mouse anti-BrdU monoclonal antibody at room temperature for 20 min in dilution buffer (0.1% (w/v) BSA, 0.5% (v/v) Tween-20 in PBS) followed by another resuspension in washing buffer. The labeled cells were detected in the green (FL1) channel of a flow cytometer, CyAn-ADP (Dako cytomation, Carpinteria, CA). FITC-conjugated mouse monoclonal IgG1 was used as isotype control.
Cell viability was estimated by the enzymatic conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan crystals in live cells. Formazan was dissolved in dimethyl sulfoxide at 90 min after addition of MTT (0.5 mg/ml) to the culture medium, and quantified by a spectrophotometer or a microplate reader at 560 nm.
Annexin-V and propidium iodide binding assay
The OPC cultures were maintained in 60 mm dishes and subjected to various experimental treatments. At 0, 24, and 48 h after these treatments, the culture medium containing detached dead cells was collected, and the attached cells were washed once with 2 ml of Ca2+ and Mg2+-free HBSS. The attached cells were removed from the plate by exposure to 0.5 ml of 0.05% trypsin at 37°C for 2 min, suspended in 2 ml of GM with 625 μg/ml trypsin inhibitor, and collected into a 15 ml tube together with the saved medium and the Ca2+ and Mg2+-free HBSS used for wash. After centrifuge at 520 xg for 10 min, the pellet was resuspended into 0.4 ml of binding buffer (0.1 M HEPES, pH 7.4; 140 mM NaCl; 2.5 mM CaCl2; 0.45% (w/v) D-glucose). Five μl of FITC-conjugated annexin-V solution and propidium iodide (PI; 8 μg/ml at final concentration) were added into 0.1 ml of the cell suspension. After incubation at room temperature for 15 min in the dark, 0.3 ml of the binding buffer was added to the cell suspension. To determine the absolute number of cells in each preparation, Flow-Count™ fluorospheres were added at a concentration of 19 beads/μl just before flow cytometry by CyAn-ADP (DakoCytomation, Carpinteria, CA, USA). Fluorescence of annexin-V-FITC and PI were detected in FL-1 and FL-4 channels, respectively. Gatings and data acquisition and analysis were carried out using Summit software (DakoCytomation) as described previously .
Cell death and loss of mitochondrial membrane potential assay
Rat OPCs cultured in 24-well plates were treated with the GM or the GM supplemented with IFNγ for 12, 18, and 24 h. Prior to collection, cells were incubated with tetramethylrhodamine ethyl ester (TMRE, 0.1 μM) at 37°C for 30 min. Then, culture medium containing dead cells was collected, and cells were washed once with 0.5 ml of the Ca2+ and Mg2+-free HBSS. Attached cells were removed with 150 μl of 0.05% trypsin for 1 min, suspended in 1 ml of the GM, and collected into a 15-ml tube together with the saved medium and the Ca2+ and Mg2+-free HBSS used for washing. After centrifugation with 1500 rpm for 5 min, the supernatant was aspirated and the pellet was kept on ice. Pellets were resuspended with 0.5 ml PBS containing 5 μM DAPI and 0.1% BSA immediately prior to analysis by flow cytometry employing a Cyan-ADP Flow Cytometer (DakoCytomation). Live and dead cell populations were gated as described previously , and TMRE and DAPI were detected in the FL-2 and the FL-6, respectively.
Real-time PCR analyses were performed by MX3005P (Stratagene, La Jolla, CA, USA) using TaqMan® Assay-on-Demand™ assay kits (assay nos.: Rn00561424_m1, Mm00515204_m1, Rn01764369_m1, Rn01435145_m1, Rn01500522_m1, Rn01762216_g1 and Rn01751474_m1 for detection of IRF1, IRF2, IRF3, IRF4, IRF5, IRF8 and interferon gamma induced GTPase (IGTP) cDNA, respectively) . For detection of IRF6, IRF7, and IRF9 cDNA, each set of primers and a probe was obtained from Applied Biosystems as a Custom TaqMan® Gene Expression Assay, because the kits for these cDNA were not available at the time of these experiments. For standardization, GAPDH cDNA levels were quantified with TaqMan Rodent GAPDH Control Reagents according to the manufacturer's instructions, and the absolute cDNA amounts were expressed as ratios to GAPDH cDNA. We present representative data from at least two independent analyses for each mRNA.
For the forced expression vectors, the open reading frame of rat IRF1 or IRF8 was inserted in the pcDNA3.1 mammalian expression vector followed by the internal ribosome entry site (IRES) and humanized Renilla reniformis green fluorescent protein (hrGFP, Stratagene) in order to facilitate identification of transfected cells by flow cytometry or by fluorescence microscopy. The expression vector for the dominant-negative form of IRF1 (IRF1DN-hrGFP) and was constructed by inserting the coding sequence of truncated rat IRF1 (amino acids 1 to 144) into the pcDNA3.1 mammalian expression vector. The truncated IRF1 coding sequence was fused to hrGFP in frame with a spacer sequence, Pro-Gly-Gly-Gly-Gly-Pro (P4GP) hinge, in order to facilitate identification of transfected cells and to evaluate the intracellular localization and stability of the dominant negative protein. For forced double expression of IRF1 and IRF8, the expression construct for IRF8 lacking hrGFP reporter (PCMV-IE-IRF8-pA) was prepared by inserting the open reading frame of rat IRF8 into pcDNA3.1.
Transfection by electroporation
Trypsinized OPCs (2 × 106) were resuspended in 100 μl of N1 medium with 10 μg plasmid DNA or 2 μM siRNA, and put into a 2 mm cuvette. A square pulse with 110 mV for 25 msec was applied to the mixture of cells and plasmid DNA with BioRad GenePulser Xcell (BioRad, Hercules, CA, USA). Cells were resuspended into GM, plated on 24 well plates, and subjected to further experimental procedures.
Data are presented as mean ± SD unless otherwise noted. Statistical significance was determined by two-tailed ANOVA followed by Student-Newman-Keuls post hoc test.
IFNβ is far less cytotoxic to OPCs than IFNγ
This far less proapoptotic effect of IFNβ on OPCs was not a consequence of less equivalent biological activity of IFNβ at 1 kU/ml compared to IFNγ at 100 ng/ml. First, a higher concentration of IFNβ, 3 kU/ml, also failed to induce caspase-3-like protease activity in OPCs (Figure. 2D). Second, as far as determined by transcriptional induction of IFNγ induced GTPase (IGTP), IFNβ at 0.3 kU/ml or higher was sufficient to induce maximal levels of IGTP mRNA (Figure. 2E). Third, based on the standard anti-viral assay to measure the biological activities of IFNs , 100 ng/ml IFNγ corresponds to approximately 0.1 to 1 kU/ml, which is almost comparable to the biological unit of IFNβ used in this study. We therefore compared the effects of IFNγ and IFNβ at 100 ng/ml and 1 kU/ml, respectively, in further experiments.
Depolarization of the mitochondrial membrane potential precedes IFNγ-induced OPC apoptosis
IRF1 and IRF8 are preferentially up-regulated in OPCs treated with IFNγ compared to those treated with IFNβ
IRF1 mediates IFNγ-induced OPC apoptosis
IRF8 enhances IFNγ-induced apoptosis of OPC
Although overexpression of IRF8 itself was not sufficient to induce OPC apoptosis, it remained to be clarified whether overexpressed IRF8 enhanced IFNγ-induced OPC apoptosis. To examine this, OPCs were transfected with PCMV-IE-IRF8-IRES-hrGFP-pA, and then treated with IFNγ at 24 h after transfection. Numbers of preapoptotic (TMRE-/DAPI-) cells were significantly increased in IRF8 overexpressing OPCs, compared with those transfected with the control vector, at 24 h after addition of IFNγ (Figure. 8B).
Proapoptotic effects of IFNγ and at most minimal cytotoxic effects of IFNβ on OPCs have been reported previously [4–9, 12, 13]. In the present study, however, we have directly compared effects of IFNγ and IFNβ on OPCs in the same in vitro condition, and confirmed a substantial difference in proapoptotic effects between the two IFNs. Furthermore, IFNβ was not protective against IFNγ-induced OPC apoptosis, despite several prior reports that IFNβ antagonizes IFNγ signaling [39–43]. As far as we could determine by transcriptional induction of IRF1, simultaneous application of IFNβ failed to reduce IFNγ-mediated robust induction of IRF1 . Although the mechanisms underlying the beneficial therapeutic effects of IFNβ on relapsing-remitting MS are still largely unknown, recent studies have indicated that IFNβ and type I IFN receptor-mediated signaling limit CNS autoimmunity by regulating innate immune responses in peripheral tissues [44, 45] and the production and properties of TH17 cells, a pathogenic T helper subset largely responsible for CNS autoimmunity . Despite the beneficial effects of IFNβ which is further ensured by far less cytotoxicity of IFNβ to OPCs, we observed that IFNβ did inhibit the cell cycle in OPCs, though to a lesser extent than IFNγ. It is thus conceivable that, as demonstrated by Trebst et al., IFNβ attenuates the endogenous capability for remyelination, which is presumably masked by its profound beneficial effects on the immune system.
Based on the marked difference in proapoptotic effects between IFNγ and IFNβ on OPCs, our next aim in this study was to identify those ISGs responsible for IFNγ-mediated OPC apoptosis. IFNγ induces robust and sustained elevation of IRF1, whereas IFNβ elicits only a transient elevation of IRF1, which ends up being undetectable at the protein level at 24 h after treatment, indicating that IRF1 is a candidate for such an ISG . In support of this, Balabanov's group has recently reported that, using a lentiviral expression system, down-regulation of IRF1 by IRF1 shRNA partially protected against IFNγ-induced OPC apoptosis, and that forced expression of IRF1 reduced the viability of OPCs . We employed a different forced expression system and a dominant negative approach in this study, and confirmed significant involvement of IRF1 in IFNγ-mediated OPC apoptosis. We further provided direct evidence for activation of the mitochondrial apoptotic pathway by overexpression of IRF1 alone. Notably, however, both approaches used in our study and the study by Balabanov's group to down-regulate IRF1-mediated transcription failed to completely inhibit IFNγ-mediated apoptotic events, suggesting possible functional redundancy of the ISGs involved in IFNγ-mediated transcriptional activation leading to apoptosis of OPCs. Given the structural and functional similarity among members of the IRF family and their known interactions, transcriptional activity of IRF1 is likely to be modified or compensated by the other members of the IRF protein family.
In an effort to obtain a comprehensive expression profile of the IRF family in OPCs stimulated by either IFNγ or IFNβ, we found that IRF8 was also up-regulated by IFNγ but not by IFNβ. IRF8 was originally identified as a protein that binds to the ISRE in the promoter region of the MHC class I gene H-2LD , and was believed to be expressed exclusively in the hematopoietic lineage (Reviewed in ). Our result indicates that OPCs are also capable of expressing IRF8 in response to IFNγ. In contrast to overexpression of IRF1, however, overexpression of IRF8 alone resulted in only transient depolarization of the mitochondrial membrane in OPCs, but failed to reduce their viability. More importantly, despite this weak proapoptotic effect of overexpressed IRF8 itself, it significantly enhanced the IFNγ-induced apoptosis and proapoptotic effect of overexpressed IRF1 in OPCs even in the absence of IFNγ. Unlike other IRF members, IRF8 is capable of binding to the target DNA motif only following association with IRF1, IRF2 or non-IRF transcription factors such as PU.1 [36, 49]. As an example, IRF8 and IRF1 synergistically induce several genes, such as IL-12 and iNOS [50, 51], in activated macrophages. A study from Ozato's group also demonstrated that IRF8 induced by activated STAT1 forms a multiprotein transcriptional complex with other nuclear proteins, which binds to GAS, and, in turn, potentiates transcriptional activation of the ISGs in a GAS-dependent manner . Therefore, it is conceivable that, although IRF8 alone is not sufficient to activate the apoptogenic cascade in OPCs, IRF8 enhances IFNγ-induced OPC apoptosis by interacting with other transcription factors activated by IFNγ. Indeed, IRF8 is known to function as a proapoptotic transcription factor like IRF1. IRF8-deficient mice are characterized by a myeloproliferative phenotype resulting in a syndrome similar to human chronic myelogenous leukemia . This oncogenic phenotype is attributable to cytokine hypersensitivity and apoptosis resistance of IRF8 deficient myeloid progenitor cells . During differentiation of the myeloid lineage, IRF8 down regulates anti-apoptotic genes such as Bcl-XL, one of anti-apoptotic member of the Bcl-2 family, and PTPN13, which encodes an inhibitor of Fas-mediated apoptosis [55, 56]. The anti-oncogenic roles of IRF8 are associated with its proapoptotic function in the other types of tumors as well. In colon carcinoma cells, IRF8 induced by IFNγ sensitizes them to Fas-mediated apoptosis, but the silencing of the IRF8 gene by methylation of its promoter region renders them resistance to IFNγ-mediated apoptosis .
Reduction of IRF8 by siRNA failed to enhance viability of OPCs after treatment with IFNγ, although it partially but significantly decreased the number of preapoptotic cells. However, we still could not rule out a contribution of the endogenous IRF8 in the IFNγ-induced OPC apoptosis, because the transfection of the IRF8 siRNA resulted in only a partial suppression against the robust IRF8 induction by IFNγ. Together, these results support the notion that endogenous IRF8 positively regulates the IFNγ-induced OPC apoptosis depending on its induced dosage.
We previously demonstrated that, unlike OPCs, mature myelin-producing oligodendrocytes were totally resistant to IFNγ-induced apoptosis . Nevertheless, IRF1 was similarly induced by IFNγ in mature oligodendrocytes compared with OPCs [10, 17]. We also confirmed that IFNγ induced IRF8 mRNA at similar levels in both OPCs and mature oligodendrocytes (Data not shown.). These results indicate that IRF1-mediated transcriptional activations may be necessary to activate the apoptotic cascade in OPCs, but are not sufficient. We speculate that differences in cellular context between OPCs and mature oligodendrocytes such as activities of ERK signaling are the other necessary components for IFNγ-induced OPC apoptosis as well [10, 58, 59].
Conclusions from this study are summarized as follows. First, unlike IFNγ, IFNβ is far less capable of inducing OPC apoptosis. Second, our comprehensive analysis of the IRF family members in IFNγ- and IFNβ-treated OPCs identified that IRF1 and IRF8 are preferentially up-regulated by IFNγ. Third, functional analyses of IRF1 and IRF8 revealed that not only IRF1 but also IRF8 contribute to the IFNγ-mediated OPC apoptosis. This finding will help us to identify downstream genes involved in OPC apoptosis. These transcription factors and their downstream target genes could be potential therapeutic targets to enhance remyelination in MS.
This work was supported by Research Grant of Shriners Hospitals for Children (No. 85400 to TI), Research fellowships of Shriners Hospitals for Children (to AI and MH) and US National Institute of Health grant NS025044 (to DP and TI).
- Watanabe M, Hadzic T, Nishiyama A: Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia. 2004, 46: 311-322. 10.1002/glia.20006.View ArticlePubMedGoogle Scholar
- Islam MS, Tatsumi K, Okuda H, Shiosaka S, Wanaka A: Olig2-expressing progenitor cells preferentially differentiate into oligodendrocytes in cuprizone-induced demyelinated lesions. Neurochem Int. 2009, 54: 192-198. 10.1016/j.neuint.2008.10.011.View ArticlePubMedGoogle Scholar
- Reynolds R, Dawson M, Papadopoulos D, Polito A, Di Bello IC, Pham-Dinh D, Levine J: The response of NG2-expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J Neurocytol. 2002, 31: 523-536. 10.1023/A:1025747832215.View ArticlePubMedGoogle Scholar
- Agresti C, D'Urso D, Levi G: Reversible inhibitory effects of interferon-gamma and tumour necrosis factor-alpha on oligodendroglial lineage cell proliferation and differentiation in vitro. Eur J Neurosci. 1996, 8: 1106-1116. 10.1111/j.1460-9568.1996.tb01278.x.View ArticlePubMedGoogle Scholar
- Andrews T, Zhang P, Bhat NR: TNFalpha potentiates IFNgamma-induced cell death in oligodendrocyte progenitors. J Neurosci Res. 1998, 54: 574-583. 10.1002/(SICI)1097-4547(19981201)54:5<574::AID-JNR2>3.0.CO;2-0.View ArticlePubMedGoogle Scholar
- Balabanov R, Strand K, Kemper A, Lee JY, Popko B: Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-gamma. J Neurosci. 2006, 26: 5143-5152. 10.1523/JNEUROSCI.0737-06.2006.View ArticlePubMedGoogle Scholar
- Chew LJ, King WC, Kennedy A, Gallo V: Interferon-gamma inhibits cell cycle exit in differentiating oligodendrocyte progenitor cells. Glia. 2005, 52: 127-143. 10.1002/glia.20232.View ArticlePubMedGoogle Scholar
- Lin W, Harding HP, Ron D, Popko B: Endoplasmic reticulum stress modulates the response of myelinating oligodendrocytes to the immune cytokine interferon-gamma. J Cell Biol. 2005, 169: 603-612. 10.1083/jcb.200502086.PubMed CentralView ArticlePubMedGoogle Scholar
- Vartanian T, Li Y, Zhao M, Stefansson K: Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol Med. 1995, 1: 732-743.PubMed CentralPubMedGoogle Scholar
- Horiuchi M, Itoh A, Pleasure D, Itoh T: MEK-ERK signaling is involved in interferon-gamma-induced death of oligodendroglial progenitor cells. J Biol Chem. 2006, 281: 20095-20106. 10.1074/jbc.M603179200.View ArticlePubMedGoogle Scholar
- Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L: The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clinical neurology and neurosurgery. 2008, 110: 878-885. 10.1016/j.clineuro.2007.10.020.View ArticlePubMedGoogle Scholar
- Halfpenny CA, Scolding NJ: Immune-modifying agents do not impair the survival, migration or proliferation of oligodendrocyte progenitors (CG-4) in vitro. J Neuroimmunol. 2003, 139: 9-16. 10.1016/S0165-5728(03)00125-5.View ArticlePubMedGoogle Scholar
- Heine S, Ebnet J, Maysami S, Stangel M: Effects of interferon-beta on oligodendroglial cells. J Neuroimmunol. 2006, 177: 173-180. 10.1016/j.jneuroim.2006.04.016.View ArticlePubMedGoogle Scholar
- Trebst C, Heine S, Lienenklaus S, Lindner M, Baumgartner W, Weiss S, Stangel M: Lack of interferon-beta leads to accelerated remyelination in a toxic model of central nervous system demyelination. Acta Neuropathol. 2007, 114: 587-596. 10.1007/s00401-007-0300-z.View ArticlePubMedGoogle Scholar
- Platanias LC: Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005, 5: 375-386. 10.1038/nri1604.View ArticlePubMedGoogle Scholar
- Boehm U, Klamp T, Groot M, Howard JC: Cellular responses to interferon-gamma. Annu Rev Immunol. 1997, 15: 749-795. 10.1146/annurev.immunol.15.1.749.View ArticlePubMedGoogle Scholar
- Itoh T, Horiuchi M, Itoh A: Interferon-triggered transcriptional cascades in the oligodendroglial lineage: a comparison of induction of MHC class II antigen between oligodendroglial progenitor cells and mature oligodendrocytes. J Neuroimmunol. 2009, 212: 53-64. 10.1016/j.jneuroim.2009.04.021.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang Y, Ren Z, Tao D, Tilwalli S, Goswami R, Balabanov R: STAT1/IRF-1 signaling pathway mediates the injurious effect of interferon-gamma on oligodendrocyte progenitor cells. Glia. 2010, 58: 195-208. 10.1002/glia.20912.View ArticlePubMedGoogle Scholar
- Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T: Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell. 1989, 58: 729-739. 10.1016/0092-8674(89)90107-4.View ArticlePubMedGoogle Scholar
- Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T: Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell. 1988, 54: 903-913. 10.1016/S0092-8674(88)91307-4.View ArticlePubMedGoogle Scholar
- Taniguchi T, Ogasawara K, Takaoka A, Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001, 19: 623-655. 10.1146/annurev.immunol.19.1.623.View ArticlePubMedGoogle Scholar
- Honda K, Taniguchi T: IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006, 6: 644-658. 10.1038/nri1900.View ArticlePubMedGoogle Scholar
- Ozato K, Tailor P, Kubota T: The interferon regulatory factor family in host defense: mechanism of action. J Biol Chem. 2007, 282: 20065-20069. 10.1074/jbc.R700003200.View ArticlePubMedGoogle Scholar
- Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008, 26: 535-584. 10.1146/annurev.immunol.26.021607.090400.View ArticlePubMedGoogle Scholar
- Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T: Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J. 1999, 18: 5028-5041. 10.1093/emboj/18.18.5028.PubMed CentralView ArticlePubMedGoogle Scholar
- Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, Taniguchi T: Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell. 1990, 63: 303-312. 10.1016/0092-8674(90)90163-9.View ArticlePubMedGoogle Scholar
- Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M, Taniguchi T: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 1993, 259: 971-974. 10.1126/science.8438157.View ArticlePubMedGoogle Scholar
- Agresti C, Bernardo A, Del Russo N, Marziali G, Battistini A, Aloisi F, Levi G, Coccia EM: Synergistic stimulation of MHC class I and IRF-1 gene expression by IFN-gamma and TNF-alpha in oligodendrocytes. Eur J Neurosci. 1998, 10: 2975-2983. 10.1111/j.1460-9568.1998.00313.x.View ArticlePubMedGoogle Scholar
- Itoh T, Beesley J, Itoh A, Cohen AS, Kavanaugh B, Coulter DA, Grinspan JB, Pleasure D: AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J Neurochem. 2002, 81: 390-402. 10.1046/j.1471-4159.2002.00866.x.View ArticlePubMedGoogle Scholar
- Moran J, Itoh T, Reddy UR, Chen M, Alnemri ES, Pleasure D: Caspase-3 expression by cerebellar granule neurons is regulated by calcium and cyclic AMP. J Neurochem. 1999, 73: 568-577. 10.1046/j.1471-4159.1999.0730568.x.View ArticlePubMedGoogle Scholar
- Kawanokuchi J, Mizuno T, Kato H, Mitsuma N, Suzumura A: Effects of interferon-beta on microglial functions as inflammatory and antigen presenting cells in the central nervous system. Neuropharmacology. 2004, 46: 734-742. 10.1016/j.neuropharm.2003.11.007.View ArticlePubMedGoogle Scholar
- Vitale G, van Koetsveld PM, de Herder WW, van der Wansem K, Janssen JA, Colao A, Lombardi G, Lamberts SW, Hofland LJ: Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells. Am J Physiol Endocrinol Metab. 2009, 296: E559-566. 10.1152/ajpendo.90770.2008.View ArticlePubMedGoogle Scholar
- Meager A: Quantification of interferons by anti-viral assays and their standardization. Lymphokines and Interferons--A Practical Approach. Edited by: Clemens MJ, Morris AG, Gearing AJH. 1987, Oxford: IRL, 129-147.Google Scholar
- Holohan C, Szegezdi E, Ritter T, O'Brien T, Samali A: Cytokine-induced beta-cell apoptosis is NO-dependent, mitochondria-mediated and inhibited by BCL-XL. J Cell Mol Med. 2008, 12: 591-606. 10.1111/j.1582-4934.2007.00191.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Panaretakis T, Hjortsberg L, Tamm KP, Björklund AC, Joseph B, Grandér D: Interferon alpha induces nucleus-independent apoptosis by activating extracellular signal-regulated kinase 1/2 and c-Jun NH2-terminal kinase downstream of phosphatidylinositol 3-kinase and mammalian target of rapamycin. Mol Biol Cell. 2008, 19: 41-50. 10.1091/mbc.E07-04-0358.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharf R, Meraro D, Azriel A, Thornton AM, Ozato K, Petricoin EF, Larner AC, Schaper F, Hauser H, Levi BZ: Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem. 1997, 272: 9785-9792. 10.1074/jbc.272.15.9785.View ArticlePubMedGoogle Scholar
- Bovolenta C, Driggers PH, Marks MS, Medin JA, Politis AD, Vogel SN, Levy DE, Sakaguchi K, Appella E, Coligan JE: Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc Natl Acad Sci USA. 1994, 91: 5046-5050. 10.1073/pnas.91.11.5046.PubMed CentralView ArticlePubMedGoogle Scholar
- Au WC, Pitha PM: Recruitment of multiple interferon regulatory factors and histone acetyltransferase to the transcriptionally active interferon a promoters. J Biol Chem. 2001, 276: 41629-41637. 10.1074/jbc.M105121200.View ArticlePubMedGoogle Scholar
- Ling PD, Warren MK, Vogel SN: Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of Ia antigen in murine macrophages. J Immunol. 1985, 135: 1857-1863.PubMedGoogle Scholar
- Inaba K, Kitaura M, Kato T, Watanabe Y, Kawade Y, Muramatsu S: Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens. J Exp Med. 1986, 163: 1030-1035. 10.1084/jem.163.4.1030.View ArticlePubMedGoogle Scholar
- Satoh J, Paty DW, Kim SU: Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology. 1995, 45: 367-373.View ArticlePubMedGoogle Scholar
- Ransohoff RM, Devajyothi C, Estes ML, Babcock G, Rudick RA, Frohman EM, Barna BP: Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol. 1991, 33: 103-112. 10.1016/0165-5728(91)90054-B.View ArticlePubMedGoogle Scholar
- Lu HT, Riley JL, Babcock GT, Huston M, Stark GR, Boss JM, Ransohoff RM: Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med. 1995, 182: 1517-1525. 10.1084/jem.182.5.1517.View ArticlePubMedGoogle Scholar
- Prinz M, Schmidt H, Mildner A, Knobeloch KP, Hanisch UK, Raasch J, Merkler D, Detje C, Gutcher I, Mages J, Lang R, Martin R, Gold R, Becher B, Brück , Kalinke U: Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity. 2008, 28: 675-686. 10.1016/j.immuni.2008.03.011.View ArticlePubMedGoogle Scholar
- Yen JH, Ganea D: Interferon beta induces mature dendritic cell apoptosis through caspase-11/caspase-3 activation. Blood. 2009, 114: 1344-1354. 10.1182/blood-2008-12-196592.PubMed CentralView ArticlePubMedGoogle Scholar
- Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F: T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009, 65: 499-509. 10.1002/ana.21652.View ArticlePubMedGoogle Scholar
- Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, Levi BZ, Flanagan JR, Appella E, Ozato K: An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci USA. 1990, 87: 3743-3747. 10.1073/pnas.87.10.3743.PubMed CentralView ArticlePubMedGoogle Scholar
- Tamura T, Ozato K: ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res. 2002, 22: 145-152. 10.1089/107999002753452755.View ArticlePubMedGoogle Scholar
- Wang IM, Contursi C, Masumi A, Ma X, Trinchieri G, Ozato K: An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J Immunol. 2000, 165: 271-279.View ArticlePubMedGoogle Scholar
- Liu J, Guan X, Tamura T, Ozato K, Ma X: Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequence-binding protein. J Biol Chem. 2004, 279: 55609-55617. 10.1074/jbc.M406565200.View ArticlePubMedGoogle Scholar
- Xiong H, Zhu C, Li H, Chen F, Mayer L, Ozato K, Unkeless JC, Plevy SE: Complex formation of the interferon (IFN) consensus sequence-binding protein with IRF-1 is essential for murine macrophage IFN-gamma-induced iNOS gene expression. J Biol Chem. 2003, 278: 2271-2277. 10.1074/jbc.M209583200.View ArticlePubMedGoogle Scholar
- Contursi C, Wang IM, Gabriele L, Gadina M, O'Shea J, Morse HC, Ozato K: IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNgamma-responsive promoters in macrophages. Proc Natl Acad Sci USA. 2000, 97: 91-96. 10.1073/pnas.97.1.91.PubMed CentralView ArticlePubMedGoogle Scholar
- Holtschke T, Löhler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkemagel RM, Morse HC, Ozato K, Horak I: Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996, 87: 307-317. 10.1016/S0092-8674(00)81348-3.View ArticlePubMedGoogle Scholar
- Scheller M, Foerster J, Heyworth CM, Waring JF, Lohler J, Gilmore GL, Shadduck RK, Dexter TM, Horak I: Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood. 1999, 94: 3764-3771.PubMedGoogle Scholar
- Huang W, Zhu C, Wang H, Horvath E, Eklund EA: The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem. 2008, 283: 7921-7935. 10.1074/jbc.M706710200.View ArticlePubMedGoogle Scholar
- Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P, Giese NA, Ozato K, Morse HC: Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med. 1999, 190: 411-421. 10.1084/jem.190.3.411.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu K, Abrams SI: Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. J Immunol. 2003, 170: 6329-6337.View ArticlePubMedGoogle Scholar
- Kirchhoff S, Hauser H: Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis. Oncogene. 1999, 18: 3725-3736. 10.1038/sj.onc.1202704.View ArticlePubMedGoogle Scholar
- Mebratu YA, Dickey BF, Evans C, Tesfaigzi Y: The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death. J Cell Biol. 2008, 183: 429-439. 10.1083/jcb.200801186.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.